Casadevall 

Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side-effects than the current vaccine.

The research is significant because anthrax is considered a major bioterrorism threat. The current anthrax vaccine is intended mainly for members of the armed forces serving in areas considered high-risk and for individuals involved in homeland biosecurity.

“Our research was motivated by the fact that the current anthrax vaccine has significant limitations and there is great need for a better one,” said lead author Nareen Abboud, PhD, an Einstein postdoctoral fellow and lead author of the study, which appears in the current issue of The Journal of Biological Chemistry. The study’s senior author is Arturo Casadevall (pictured above), MD, PhD, Leo and Julia Forchheimer Professor and chairman of microbiology & immunology. Read more. 

Watch video.

 

Leave a Reply